Kidney Week Educational Symposia-HIF-PHIs Offer Hope for Anemia in CKD

Video Transcription

Video Summary

The transcript covers a debate on treating anemia in chronic kidney disease (CKD), contrasting traditional erythropoiesis-stimulating agents (ESAs) with newer oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). CKD anemia is multifactorial, driven largely by inadequate erythropoietin (EPO) plus iron deficiency, inflammation, and reduced RBC survival. ESAs improve quality of life and reduce transfusions but have drawbacks (injections, cost, hypertension, thromboembolism, and cardiovascular risk), and 5–10% of patients are hyporesponsive.<br /><br />HIF-PHIs stabilize HIF (especially HIF-2 via PHD2 inhibition), increasing endogenous EPO and improving iron handling (lower hepcidin, greater mobilization/absorption). Clinical trials show HIF-PHIs effectively raise hemoglobin, maintain targets, and reduce transfusions and rescue therapy, with some metabolic effects (e.g., LDL reduction).<br /><br />Safety remains the central controversy. One speaker argues broad readiness, citing generally non-inferior major adverse cardiovascular event (MACE) results and trial-design issues affecting analyses (dialysis transitions, exposure differences, FDA interpretation). The opposing speaker emphasizes that non-inferiority margins may permit clinically meaningful MACE increases, notes vanadustat showed higher MACE in non-dialysis CKD, highlights unknown long-term systemic HIF risks (tumor growth, retinopathy), and points to limited patient-centered quality-of-life data.

Asset Subtitle

Moderators: Tetsuhiro Tanaka

Speakers:

Introduction: Overview of Anemia in CKD - Tetsuhiro Tanaka
HIF-PHIs for the Treatment of Anemia in CKD: Ready for Broad Use - Daniel Coyne
HIF-PHIs for the Treatment of Anemia in CKD: Not So Fast! - Joshua Kaplan

Meta Tag

Date 11/6/2021

Pathway 1 Chronic Kidney Disease

Session ID 408408

Session Type ES - Educational Symposium

Keywords

chronic kidney disease anemia

erythropoiesis-stimulating agents

HIF prolyl-hydroxylase inhibitors

hypoxia-inducible factor stabilization

hepcidin and iron metabolism

hemoglobin target maintenance

major adverse cardiovascular events

vanadustat safety controversy